These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 16606766)

  • 1. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
    Galimberti D; Schoonenboom N; Scheltens P; Fenoglio C; Bouwman F; Venturelli E; Guidi I; Blankenstein MA; Bresolin N; Scarpini E
    Arch Neurol; 2006 Apr; 63(4):538-43. PubMed ID: 16606766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
    Galimberti D; Fenoglio C; Lovati C; Venturelli E; Guidi I; Corrà B; Scalabrini D; Clerici F; Mariani C; Bresolin N; Scarpini E
    Neurobiol Aging; 2006 Dec; 27(12):1763-8. PubMed ID: 16307829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease.
    Popp J; Bacher M; Kölsch H; Noelker C; Deuster O; Dodel R; Jessen F
    J Psychiatr Res; 2009 May; 43(8):749-53. PubMed ID: 19038405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
    Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A
    Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
    Hernanz A; De la Fuente M; Navarro M; Frank A
    Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1.
    Lahrtz F; Piali L; Nadal D; Pfister HW; Spanaus KS; Baggiolini M; Fontana A
    Eur J Immunol; 1997 Oct; 27(10):2484-9. PubMed ID: 9368600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.
    Apostolova LG; Dutton RA; Dinov ID; Hayashi KM; Toga AW; Cummings JL; Thompson PM
    Arch Neurol; 2006 May; 63(5):693-9. PubMed ID: 16682538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
    Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K
    Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF cortisol in Alzheimer's disease and mild cognitive impairment.
    Popp J; Schaper K; Kölsch H; Cvetanovska G; Rommel F; Klingmüller D; Dodel R; Wüllner U; Jessen F
    Neurobiol Aging; 2009 Mar; 30(3):498-500. PubMed ID: 17716786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
    Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
    Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
    Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
    Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
    Rothenbacher D; Müller-Scholze S; Herder C; Koenig W; Kolb H
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):194-9. PubMed ID: 16239601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
    Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
    Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facial emotion recognition deficit in amnestic mild cognitive impairment and Alzheimer disease.
    Spoletini I; Marra C; Di Iulio F; Gianni W; Sancesario G; Giubilei F; Trequattrini A; Bria P; Caltagirone C; Spalletta G
    Am J Geriatr Psychiatry; 2008 May; 16(5):389-98. PubMed ID: 18403572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.